Traditional cancer therapies like chemotherapy are associated with a wide array of toxicities. This is because, while the cancer cells are more sensitive than non-cancerous cells, the drugs still get into, and can kill healthy tissue. But, what if the therapy was designed in such a way that it wouldn’t become active until it was inside the tumor? This would spare healthy tissue from toxicities AND improve therapeutic efficiency.

Video description T cell exhaustion can severely hinder anti-cancer immune responses and several therapeutic modalities – including the most successful drug in medicine Merck’s KEYTRUDA – are designed to combat it. A paper published in Nature Immunology on November 8th our of the University of Pittsburgh describes how exhausted T

Description Last week, Autolus announced that they had received FDA approval for their autologous CAR-T cell therapy obe-cel (AUCATZYL) for use in adult r/r B-ALL. This is amazing news for the patients and the company – congrats to both! In this video, I explain the data that led to the